Insulet (PODD) financial statements
- FY2025 revenue
- $2.7B▲ +30.7%
- FY2025 net income
- $247M▼ −40.9%
- FY2025 diluted EPS
- $3.48▼ −39.8%
- FY2025 free cash flow
- $378M▲ +23.7%
Insulet income statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Revenue | 2,708 | 2,072 | 1,697 |
| Gross profit | 1,940 | 1,446 | 1,160 |
| Operating income | 474 | 309 | 220 |
| Pretax income | 340 | 300 | 215 |
| Net income | 247 | 418 | 206 |
| Diluted earnings per share | 3.48 | 5.78 | 2.94 |
Insulet balance sheet
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Cash and cash equivalents | 716 | 953 | 704 |
| Total assets | 3,190 | 3,088 | 2,588 |
| Total liabilities | 1,675 | 1,876 | 1,856 |
| Total equity | 1,515 | 1,212 | 733 |
| Long-term debt | 931 | 1,296 | 1,366 |
Insulet cash flow statement
| USD millions | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period ended | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 |
| Operating cash flow | 569 | 430 | 146 |
| Capital expenditure | -192 | -125 | -76 |
| Free cash flow (derived) | 378 | 305 | 70 |
| Share repurchases | -60 | 0 | 0 |
Quarterly highlights
| USD millions | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 |
|---|---|---|---|---|
| Period ended | 30 Jun 2026 | 31 Mar 2026 | 31 Dec 2025 | 30 Sep 2025 |
| Revenue (derived) | 802 | 762 | 784 | 706 |
| Operating income (derived) | 130 | 122 | 146 | 118 |
| Net income (derived) | 95 | 91 | 102 | 88 |
| Diluted earnings per share | 1.37 | 1.30 | n/a | 1.24 |
| Operating cash flow (derived) | 88 | 114 | 183 | 126 |
| Total assets | 3,165 | 2,987 | 3,190 | 3,029 |
Insulet major shareholders
| Holder | Share of class | Shares | Filed |
|---|---|---|---|
| BlackRock, Inc. | 7.7% | 5,337,778 | 27 October 2026 |
| Vanguard Capital Management | 7.5% | 5,277,842 | 30 April 2026 |
Insulet 10-K and SEC filings
| Filed | Form | Type | Description |
|---|---|---|---|
| 21 September 2026 | 8-K | Current report | Current report |
| 16 September 2026 | 8-K | Current report | Current report |
| 10 September 2026 | 8-K | Current report | Current report |
| 5 August 2026 | 10-Q | Quarterly report | Quarterly report |
| 5 August 2026 | 8-K | Current report | Current report |
| 25 June 2026 | 8-K | Current report | Current report |
| 26 May 2026 | 8-K | Current report | Current report |
| 21 May 2026 | 8-K | Current report | Current report |
Common questions
What was Insulet's revenue in fiscal 2025?
Insulet reported $2.7 billion in revenue for fiscal 2025, the year ended 31 December 2025, up 30.7% from fiscal 2024.
What was Insulet's net income in fiscal 2025?
Insulet reported net income of $247 million for fiscal 2025, the year ended 31 December 2025, down 40.9% from fiscal 2024. Diluted earnings per share were $3.48.
What was Insulet's free cash flow in fiscal 2025?
Insulet had $378 million in free cash flow in fiscal 2025. Operating cash flow was $569 million and capital expenditure was $192 million.
What were Insulet's total assets at the end of fiscal 2025?
Insulet reported total assets of $3.2 billion at the end of fiscal 2025, the year ended 31 December 2025.
How much Insulet history does each plan include?
Free covers the last 3 fiscal years of annual figures. Basic covers the last 10 fiscal years, annual and quarterly. Pro covers the full history, with first reported values and as of dates.
Get these figures through the API
5,000 free requests every month. No card needed.